Incyte Co. (NASDAQ:INCY) insider David W. Gryska sold 6,760 shares of Incyte stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $98.87, for a total transaction of $668,361.20. Following the completion of the transaction, the insider now owns 20,752 shares in the company, valued at approximately $2,051,750.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Incyte Co. (NASDAQ:INCY) opened at $93.06 on Friday. Incyte Co. has a 52-week low of $92.52 and a 52-week high of $153.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.81 and a current ratio of 4.82. The firm has a market cap of $19,640.00, a P/E ratio of -116.33 and a beta of 0.74.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.11. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. The firm had revenue of $381.50 million for the quarter, compared to analysts’ expectations of $360.34 million. During the same period in the previous year, the company posted $0.19 EPS. The company’s quarterly revenue was up 41.6% compared to the same quarter last year. equities analysts anticipate that Incyte Co. will post -1.32 earnings per share for the current year.

Several research firms have issued reports on INCY. Raymond James Financial restated a “buy” rating on shares of Incyte in a research report on Tuesday, December 12th. Goldman Sachs Group began coverage on shares of Incyte in a research report on Friday, October 6th. They issued a “buy” rating and a $160.00 price target on the stock. Zacks Investment Research lowered shares of Incyte from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. ValuEngine lowered shares of Incyte from a “hold” rating to a “sell” rating in a research report on Wednesday, November 29th. Finally, Oppenheimer set a $120.00 price target on shares of Incyte and gave the stock a “hold” rating in a research report on Tuesday, January 2nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $143.11.

Several large investors have recently modified their holdings of INCY. Tower Research Capital LLC TRC boosted its stake in shares of Incyte by 13.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 108 shares during the period. Seven Eight Capital LP acquired a new stake in shares of Incyte during the 2nd quarter valued at $129,000. Sun Life Financial INC boosted its stake in shares of Incyte by 9,069.2% during the 2nd quarter. Sun Life Financial INC now owns 1,192 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 1,179 shares during the period. Private Advisor Group LLC acquired a new stake in shares of Incyte during the 3rd quarter valued at $203,000. Finally, Symphony Asset Management LLC boosted its stake in shares of Incyte by 20.1% during the 2nd quarter. Symphony Asset Management LLC now owns 1,867 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 312 shares during the period. 90.74% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Incyte Co. (INCY) Insider Sells $668,361.20 in Stock” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/incyte-co-incy-insider-sells-668361-20-in-stock/1803926.html.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with Analyst Ratings Network's FREE daily email newsletter.